DMID Note-revised version

CHROMagar™ ESBL / mSuperCARBA bi-plate medium for detection of ESBL- and carbapenemase-producing *Enterobacteriaceae* from spiked stools

Delphine GIRLICH [a], Victor GROSPERRIN [a], Thierry NAAS [a,b] and Laurent DORTET [a,b*]

[a] EA7361, Université Paris-Sud, Bacteriology-Hygiene unit, APHP, Hôpital Bicêtre, Le Kremlin-Bicêtre, France

[b] Associate French National Reference Center for Antibiotic Resistance "Carbapenemase-producing Enterobacteriaceae"

*Corresponding author: Dr. Laurent DORTET

Faculté de Médecine et Université Paris Saclay, Le Kremlin-Bicêtre, 78 rue du Général Leclerc 94270 Le Kremlin-Bicêtre, France.

Phone :+33 1 45212019

Fax : +33 1 45216340

Email: laurent.dortet@aphp.fr

Running title : Bi-plate for screening ESBL-Es and CPEs

Word count : Text : 1282 words; Abstract : 49 words

ABSTRACT

The recently released CHROMagar™ ESBL/CHROMagar™ mSuperCARBA bi-plate medium was evaluated for the detection of ESBL- and carbapenemase-producing *Enterobacteriaceae*. Spiked stools were used to mimic *in vivo* stool colonization. Two-hundred enterobacterial isolates were tested. Respective sensitivities of 93.9% and 97.8% were obtained for the detection of ESBL and carbapenemase producers.

Keywords : carbapenemases, NDM, sensitivity, specificity, selective medium, chromogenic

Resistance to broad-spectrum cephalosporins and subsequently to carbapenems spreads rapidly among *Enterobacteriaceae* at an alarming rate, resulting in both nosocomial and community-acquired infections primarily due to the production of extended-spectrum β-lactamases (ESBLs) and/or carbapenemases (1, 2). Targeted surveillance of high-risk patients and screening are essential to prevent outbreaks of nosocomial infections by these organisms. In *Enterobacteriaceae*, clinically relevant carbapenemases belong to the Ambler class A (KPC-type), Ambler class B metallo-β-lactamases (NDM, VIM and IMP), and Ambler class D enzymes (OXA-48-like) (3). The level of resistance to carbapenems conferred by these carbapenemase producers may vary widely, making their detection difficult when just based on their *in vitro* susceptibility profile (4). ESBL are enzymes that mediate resistance to penicillins, extended-spectrum third generation cephalosporins (3GC) and monobactams. ESBL-producing *Enterobacteriaceae* appeared in the 1980s, and have since become highly prevalent in nosocomial infections, mainly due to *Escherichia coli* and *Klebsiella* spp. ChromID ESBL (bioMérieux) and CHROMagar™ ESBL (CHROMagar, Paris, France) are very useful for the detection of ESBL enterobacterial producers, nevertheless their ability to detect isolates producing OXA-48-like carbapenemase alone is limited (5, 6). Consequently, the detection of all carbapenemase-producing *Enterobacteriaceae* (CPE), including OXA-48-like producers, is based on the inoculation of at least two media able to efficiently identify (i) all types of carbapenemases with the exception of OXA-48-like enzymes (*e.g.* ChromID® CARBA medium, bioMérieux) and (ii) specifically OXA-48-like producers (*e.g.* ChromID® OXA-48 medium, bioMérieux). These two media are now marketed in a single bi-plate, the ChromID® CARBA SMART medium that has been

reported to efficiently detect all CPEs. However, this medium is designed for the screening of CPEs and not for ESBL-producers.

Another medium had already been developed for the detection of all CPEs, including OXA-48-like carbapenemase-producers, the SUPERCARBA medium (7). The initial SUPERCARBA medium was further modified to improve its stability and facilitate the presumptive identification of the enterobacterial species by the addition of chromogenic molecules. This improved medium, named mSuperCARBA (CHROMagar Ltd., France), was demonstrated to be reliable for the screening of CPE (8-11). However, as observed with the ChromID® CARBA SMART medium, this single plate medium is not suitable for screening of ESBL producers.

Recently, the selective bi-plate medium CHROMagar™ ESBL/CHROMagar™ mSuperCARBA (CHROMagar Ltd., France) was designed for the rapid identification of ESBL-producing and carbapenem-resistant *Enterobacteriaceae*. The aim of the present study was to evaluate the performance of this bi-plate medium using spiked stool samples with a collection of well-characterized CPE and ESBL-producers at the molecular level.

Two hundred and three enterobacterial isolates were tested (Table 1), including 137 carbapenemase-producers [30 Ambler class A (KPC, Sme, IMI, GES-5, FRI-1), 50 Ambler class B (IMP, VIM, GIM-1, NDM-type), 43 Ambler class D (OXA-48-type and OXA-372), 14 multiple carbapenemase producers] and 62 non carbapenemase-producers [ESBL with or without impaired outer-membrane (n=26), cephalosporinase-producers with or without an altered outer-membrane (n=27), concomitant ESBL and over-expressed cephalosporinase-producers (n=4), K1 penicillinase or extended-spectrum oxacillinases-producers (n=5)]. The β-lactamase content of all these isolates

was characterized by-end-point PCR followed by Sanger sequencing or by whole genome sequencing. In addition the Carba NP test was also performed on all isolates as previously described (12). Fully-susceptible strains of *E. coli* ATCC 25922 and *K. pneumoniae* CIP53153, and ESBL-producing strains of *E. coli* CIP103983 (TEM-4) and *K. pneumoniae* ATCC 700603 (SHV-18) were used as controls (not included in the Table of results).

CHROMagar™ ESBL/mSuperCARBA is a ready-to-use bi-plate with a shelf life of 60 days at +4°C (+2°C to +12°C). Bacterial suspensions with a 0.5 McFarland (inoculum of ~5 x 10^7 to 10^8 CFU/mL) of the different isolates were serially diluted (10-fold dilutions) in water. Spiked fecal samples were prepared by adding 100 µL of each dilution to 900 µL of fecal suspension obtained by resuspending 4 g of freshly pooled feces from four healthy volunteers in 40 mL of distilled water, as previously described (13). A fecal suspension without spiking was used as negative control. The lowest detection limits were determined by plating 10 µl of each spiked fecal samples on CHROMagar™ ESBL/mSuperCARBA medium. Viable bacteria were counted after 24 h of culture at 37°C. The lowest detection limit (LOD) corresponds the minimum number of bacteria that must be present in the sample to obtain a growth on the selective medium. In order to compare both selective media, the cut-off value was arbitrarily set at > 1 x 10^4 CFU/mL. A minimal concentration greater than 1 x 10^4 CFU/mL was considered as non-detection and sensitivity and specificity values were determined accordingly (Table 1).

Considering the 62 non-carbapenemase producers, all ESBL-producers with (n=13) or without an altered outer-membrane (n=13) grew on the CHROMagar™ ESBL medium, while 75% of the enterobacterial isolates with an acquired cephalosporinase did not grow with the exception of one DHA-2-producing *K. pneumoniae* isolate (considered as a false positive). However,

19/23 isolates with overexpression of the cephalosporinase associated with decreased altered outer membrane grew on the CHROMagar™ ESBL medium. They were falsely considered as potential ESBL-producers. Only one of the three extended-spectrum oxacillinase-producers grew on the CHROMagar™ ESBL medium (thus giving two false negatives). Finally, the two penicillinase K1 overexpressing *K. oxytoca* were also falsely detected as ESBL-producers. Overall, the sensitivity of the CHROMagar™ ESBL medium for the detection of true ESBL-producers was 93.9% [95% confidence interval (CI95) = 78.4% - 98.9%] in this study. Due to the high number of isolates with overexpressed-cephalosporinase associated with decreased outer-membrane permeability, and the absence of isolates with wild-type phenotypes, the specificity of the CHROMagar™ ESBL medium was low (24.1%). Despite this limitation in the number of susceptible isolates tested, several studies have previously demonstrated that this CHROMagar™ ESBL medium is useful for the efficient detection of ESBL producers (14, 15).

Among the 137 CPEs, all but three cultured on the CHROMagar™ mSuperCARBA medium. One Sme-1-producing *Serratia marcescens*, one NDM-1 producing *Providencia stuartii*, and one VIM-1 producing *E. coli* (Table 1) did not grow on the 'carba side of the plate', however, NDM-1 producing *P. stuartii* and VIM-1 producing *E. coli* grew on the ESBL side of the plate. As previously described with the SUPERCARBA medium, all OXA-48-like producers, known to have a lower carbapenemase activity compared to other carbapenemases (KPC, NDM, VIM, IMP), were detected irrespective of the production of an associated ESBL (7). Despite high MICs of carbapenems, most (15/23) non carbapenemase-producers with overexpression of the cephalosporinase associated with decreased outer membrane permeability did not culture on mSuperCARBA medium (Table 1). Overall, the sensitivity of the

144 CHROMagar™ mSuperCARBA medium for the detection carbapenemase
145 producers was 97.8% [CI95 = 93.2% - 99.4%] in this study. The specificity was
146 66.1% [CI95 = 52.9% - 77.4%], which corresponds mainly to the growth of
147 isolates with reduced susceptibility to carbapenems due to ESBL production
148 and/or AmpC overexpression plus impermeability of the outer membrane (Table
149 1). Due to the low specificity of both sides of the bi-plate, confirmatory tests for
150 ESBLs or carbapenemases detection should be undertaken on any growth. This
151 is a major drawback that will increase the turn around time and costs if a rapid
152 test is implemented as a confirmation test. However, this low specifity is mostly
153 due to the design of the strains collection and might be better from clinical
154 samples.
155
156 Our results suggest that the CHROMagar™ ESBL/mSuperCARBA bi-
157 plate might be a reliable tool for the concomitant screening of patients colonized
158 with ESBL and/or CPE. Currently, in France, hospitalized patients who have
159 travelled abroad are screened for the presence of CPE and ESBL-producing
160 Enterobacteriaceae. Different infection-control measures are implemented and
161 maintained according to the screening results (16): (i) standard precautions [no
162 ESBL producer, no CPE and no glycopeptide resistant *Enterococcus faecium*
163 (GRE)], (ii) contact precautions without cohorting (presence of ESBL producer
164 only), and (iii) 'extensively drug-resistant bacteria' (eXDR) control program that
165 includes dedicated staff, isolation of carrier and even cohorting, if possible, and,
166 active contact tracing and screening. This active screening of eXDR involves
167 the inoculation of three to four different media including one for the detection of
168 ESBL producers, one (bi-plate) or two media for the detection of CPE and one
169 for the screening of GRE. In the field of laboratory automation in clinical
170 microbiology (17, 18), the panel of media that can be loaded onto the sorter of

the inoculation system is limited (19). Accordingly, the implementation of CHROMAGAR™ ESBL/mSuperCARBA bi-plate might be an advantage, since this medium can replace two or three of the currently used media for the screening of ESBL and CPE producers. The cost of these bi-plates will be approximately 3.25€/plate.

ACKNOWLEDGMENTS

We thank Saoussen Oueslati and Sandrine Bernabeu for helping constituting the panel of isolates.

FUNDING

This work was partially supported by the University Paris-Sud, France and Assistance Publique - Hôpitaux de Paris, Paris, France. LD, DG and TN are members of the Laboratory of Excellence in Research on Medication and Innovative Therapeutics (LERMIT) supported by a grant from the French National Research Agency (ANR-10-LABX-33).

TRANSPARENCY DECLARATION

None to declare

REFERENCES

1. **Pitout JD, Laupland KB.** 2008. Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect Dis **8:**159-166.
2. **Rood IGH, Li Q.** 2017. Review: Molecular detection of extended spectrum-beta-lactamase- and carbapenemase-producing Enterobacteriaceae in a clinical setting. Diagn Microbiol Infect Dis **89:**245-250.
3. **Nordmann P, Dortet L, Poirel L.** 2012. Carbapenem resistance in Enterobacteriaceae: here is the storm! Trends Mol Med **18:**263-272.
4. **Landman D, Urban C, Backer M, Kelly P, Shah N, Babu E, Bratu S, Quale J.** 2010. Susceptibility profiles, molecular epidemiology, and detection of KPC-producing Escherichia coli isolates from the New York City vicinity. J Clin Microbiol **48:**4604-4607.
5. **Carrer A, Fortineau N, Nordmann P.** 2010. Use of ChromID extended-spectrum beta-lactamase medium for detecting carbapenemase-producing Enterobacteriaceae. J Clin Microbiol **48:**1913-1914.
6. **Hornsey M, Phee L, Woodford N, Turton J, Meunier D, Thomas C, Wareham DW.** 2013. Evaluation of three selective chromogenic media, CHROMagar ESBL, CHROMagar CTX-M and CHROMagar KPC, for the detection of Klebsiella pneumoniae producing OXA-48 carbapenemase. J Clin Pathol **66:**348-350.
7. **Nordmann P, Girlich D, Poirel L.** 2012. Detection of carbapenemase producers in Enterobacteriaceae by use of a novel screening medium. J Clin Microbiol **50:**2761-2766.
8. **Garcia-Fernandez S, Hernandez-Garcia M, Valverde A, Ruiz-Garbajosa P, Morosini MI, Canton R.** 2017. CHROMagar

mSuperCARBA performance in carbapenem-resistant Enterobacteriaceae isolates characterized at molecular level and routine surveillance rectal swab specimens. Diagn Microbiol Infect Dis **87:**207-209.

9. **Garcia-Quintanilla M, Poirel L, Nordmann P.** 2018. CHROMagar mSuperCARBA and RAPIDEC(R) Carba NP test for detection of carbapenemase-producing Enterobacteriaceae. Diagn Microbiol Infect Dis **90:**77-80.

10. **Genc O, Aksu E.** 2018. Chromogenic culture media or rapid immunochromatographic test: Which is better for detecting Klebsiella pneumoniae that produce OXA-48 and can they be used in blood and urine specimens. J Microbiol Methods **148:**169-173.

11. **Soria Segarra C, Larrea Vera G, Berrezueta Jara M, Arevalo Mendez M, Cujilema P, Serrano Lino M, Soria Segarra C.** 2018. Utility of CHROMagar mSuperCARBA for surveillance cultures of carbapenemase-producing Enterobacteriaceae. New Microbes New Infect **26:**42-48.

12. **Dortet L, Agathine A, Naas T, Cuzon G, Poirel L, Nordmann P.** 2015. Evaluation of the RAPIDEC(R) CARBA NP, the Rapid CARB Screen(R) and the Carba NP test for biochemical detection of carbapenemase-producing Enterobacteriaceae. J Antimicrob Chemother **70:**3014-3022.

13. **Naas T, Ergani A, Carrer A, Nordmann P.** 2011. Real-time PCR for detection of NDM-1 carbapenemase genes from spiked stool samples. Antimicrob Agents Chemother **55:**4038-4043.

14. **Grohs P, Tillecovidin B, Caumont-Prim A, Carbonnelle E, Day N, Podglajen I, Gutmann L.** 2013. Comparison of five media for detection

of extended-spectrum Beta-lactamase by use of the wasp instrument for automated specimen processing. J Clin Microbiol **51:**2713-2716.

15. **Saito R, Koyano S, Nagai R, Okamura N, Moriya K, Koike K.** 2010. Evaluation of a chromogenic agar medium for the detection of extended-spectrum ss-lactamase-producing Enterobacteriaceae. Lett Appl Microbiol **51:**704-706.

16. **Fournier S, Desenfant L, Monteil C, Nion-Huang M, Richard C, Jarlier V, The Ap-Hp Outbreaks Control G.** 2018. Efficiency of different control measures for preventing carbapenemase-producing enterobacteria and glycopeptide-resistant Enterococcus faecium outbreaks: a 6-year prospective study in a French multihospital institution, January 2010 to December 2015. Euro Surveill **23**.

17. **Croxatto A, Greub G.** 2017. Project management: importance for diagnostic laboratories. Clin Microbiol Infect **23:**434-440.

18. **Lina G, Greub G.** 2016. Automation in bacteriology: a changing way to perform clinical diagnosis in infectious diseases. Clin Microbiol Infect **22:**215-216.

19. **Croxatto A, Prod'hom G, Faverjon F, Rochais Y, Greub G.** 2016. Laboratory automation in clinical bacteriology: what system to choose? Clin Microbiol Infect **22:**217-235.

Table 1. Sensitivity of detection of the CHROMagar™ ESBL /mSuperCARBA medium from spiked fecal samples.

β-lactam resistance mechanism	Name of the strain		Species	MIC (µg/ml)			β-lactamase content	Limit of detection (UFC/ml)[b,c]	
				IPM [a]	ETP	MEM		ESBL	mSuperCARBA
NON CARBAPENEMASE PRODUCERS									
Acquired Case	2	E2	*E. coli*	0.12	0.02	0.02	DHA-1	> 1 x 10^4	> 1 x 10^4
	2	E3	*E. coli*	0.12	0.12	0.12	ACC-1	> 1 x 10^4	> 1 x 10^4
	2	E4	*K. pneumoniae*	0.12	0.5	0.12	DHA-2	1 x 10^2	> 1 x 10^4
	2	E5	*P. mirabilis*	0.25	0.12	0.12	ACC-1	> 1 x 10^4	> 1 x 10^4
ESBL	2	E6	*E. coli*	0.12	0.12	0.12	CTX-M-1	1 x 10^2	> 1 x 10^4
	2	E7	*E. coli*	0.12	0.12	0.12	CTX-M-3	1 x 10^2	> 1 x 10^4
	2	E8	*K. pneumoniae*	0.12	0.12	0.12	CTX-M-3	1 x 10^2	> 1 x 10^4
	2	E9	*E. coli*	0.12	0.12	0.12	CTX-M-14	1 x 10^2	> 1 x 10^4
	2	E10	*E. coli*	0.12	0.12	0.12	CTX-M-14	1 x 10^2	> 1 x 10^4
	2	F1	*K. pneumoniae*	0.12	0.12	0.12	CTX-M-14	1 x 10^2	> 1 x 10^4
	2	F2	*E. coli*	0.12	0.12	0.12	CTX-M-15	1 x 10^2	> 1 x 10^4
	2	F3	*E. coli*	0.12	0.12	0.12	CTX-M-15	1 x 10^2	> 1 x 10^4
	2	F4	*K. pneumoniae*	0.12	0.12	0.12	CTX-M-15	1 x 10^2	> 1 x 10^4
	2	F5	*K. pneumoniae*	0.12	0.12	0.12	CTX-M-15	1 x 10^2	> 1 x 10^4
	2	F6	*K. pneumoniae*	0.12	0.12	0.12	CTX-M-15	1 x 10^2	> 1 x 10^4
	2	F7	*E. cloacae*	0.12	0.12	0.12	CTX-M-15	1 x 10^2	> 1 x 10^4
	2	F8	*E. cloacae*	0.12	0.12	0.12	VEB-1	1 x 10^2	> 1 x 10^4
Case + impermeability	2	F9	*E. coli*	16	>32	2	↗↗↗ Case	3 x 10^2	2 x 10^2
	CNR 92 10		*E. cloacae*	0.19	1	0.12	↗↗↗ Case	1 x 10^2	> 1 x 10^4
	CNR 92 J6		*E. cloacae*	0.25	1	0.12	↗↗↗ Case	> 1 x 10^4	> 1 x 10^4
	2	F10	*E. cloacae*	0.12	1	0.12	↗↗↗ Case	1 x 10^3	> 1 x 10^4
	2	G1	*E. cloacae*	0.12	1	0.12	↗↗↗ Case	1 x 10^2	> 1 x 10^4
	2	G2	*E. cloacae*	0.25	4	0.25	↗↗↗ Case	1 x 10^2	2 x 10^3
	2	G3	*E. cloacae*	4	1.5	0.75	↗↗↗ Case	5 x 10^3	> 1 x 10^4
	2	G4	*E. cloacae*	0.19	1.5	0.12	↗↗↗ Case	1 x 10^2	> 1 x 10^4
	2	G5	*E. cloacae*	0.5	4	0.75	↗↗↗ Case	1 x 10^2	> 1 x 10^4
	2	G6	*E. cloacae*	1.5	0.75	0.25	↗↗↗ Case	1 x 10^2	> 1 x 10^4
	2	G7	*E. cloacae*	1.5	2	0.75	↗↗↗ Case	1 x 10^2	> 1 x 10^4
	2	G8	*E. cloacae*	0.5	1.5	0.38	↗↗↗ Case	1 x 10^2	> 1 x 10^4
	2	G9	*E. cloacae*	2	4	1.5	↗↗↗ Case	1 x 10^2	1 x 10^3
	2	G10	*E. cloacae*	8	>32	4	↗↗↗ Case	1 x 10^2	4 x 10^2
	2	H1	*E. cloacae*	0.5	4	0.75	↗↗↗ Case	1 x 10^2	1 x 10^2
	2	H2	*E. cloacae*	0.19	3	0.38	↗↗↗ Case	1 x 10^2	1 x 10^2
	2	H3	*E. cloacae*	1.5	3	0.75	↗↗↗ Case	1 x 10^2	> 1 x 10^4
	2	H4	*E. aerogenes*	1	4	0.75	↗↗↗ Case	1 x 10^2	> 1 x 10^4
	2	H5	*M. morgannii*	1.5	0.02	0.12	↗↗↗ Case	> 1 x 10^4	> 1 x 10^4

	CNR 87 J10		*H. alvei*	0.25	1	0.09	↗↗↗ Case	> 1 x 10^4	> 1 x 10^4
	CNR 88 A1		*H. alvei*	0.38	6	0.75	↗↗↗ Case	> 1 x 10^4	1 x 10^2
	CNR 87 F7		*S. marcescens*	0.75	0.75	0.19	↗↗↗ Case	1 x 10^2	1 x 10^2
	CNR 87 B7		*E. cloacae*	0.25	0.75	0.04	↗↗↗ Case	1 x 10^2	> 1 x 10^4
ESBL + impermeability	2	H6	*E. coli*	2	4	1	CTX-M-15	1 x 10^2	1 x 10^2
	2	H7	*K. pneumoniae*	1	>32	4	CTX-M-15 + SHV-1	1 x 10^2	1 x 10^2
	2	H8	*K. pneumoniae*	1.5	>32	4	CTX-M-15 + TEM-1 + SHV-1	1 x 10^2	1 x 10^2
	2	H9	*K. pneumoniae*	0.25	1	1	CTX-M-15 + TEM-1 + SHV-1	1 x 10^2	> 1 x 10^4
	2	H10	*K. pneumoniae*	1.5	>32	6	CTX-M-15 + SHV-11	1 x 10^2	1 x 10^2
	2	I1	*K. pneumoniae*	8	>32	4	CTX-M-15 + SHV-28 - TEM-1	1 x 10^2	1 x 10^2
	2	I2	*K. pneumoniae*	1	4	1	TEM-1 + SHV-28	1 x 10^2	1 x 10^2
	2	I3	*K. pneumoniae*	3	>32	6	CTX-M-15 + TEM-1 + SHV-11	1 x 10^2	1 x 10^2
	2	I4	*K. pneumoniae*	0.25	1	1	CTX-M-15 + TEM-1 + SHV-11	1 x 10^2	1 x 10^2
	2	I5	*K. pneumoniae*	6	> 32	> 32	CTX-M-15 + TEM-1 + SHV-11	1 x 10^2	1 x 10^2
	2	I6	*K. pneumoniae*	0.75	> 32	3	CTX-M-15 + TEM-1 + SHV-12	1 x 10^2	1 x 10^2
	2	I7	*K. pneumoniae*	1	24	0.5	CTX-M-15 +TEM-1 + SHV-11	1 x 10^2	1 x 10^2
	2	I8	*K. pneumoniae*	2	4	1	CTX-M-15 + TEM-1 + SHV-1 + OXA-1	1 x 10^2	> 1 x 10^4
Hyper K1 + impermeability	CNR 151 J9		*K. oxytoca*	2	3	0.75	↗↗↗ K1 penicillinase	1 x 10^2	1 x 10^2
	CNR 92 J7		*K. oxytoca*	1	2	0.5	↗↗↗ K1 penicillinase	1 x 10^2	> 1 x 10^4
ESBL + Case + impermeability	2	I9	*E. cloacae*	1.5	6	1	↗↗↗ Case + CTX-M-15	1 x 10^2	> 1 x 10^4
	2	I10	*E. cloacae*	2	8	1	↗↗↗ Case + CTX-M-15	1 x 10^2	> 1 x 10^4
	2	J1	*E. cloacae*	3	12	2	↗↗↗ Case + CTX-M-15	1 x 10^2	> 1 x 10^4
	2	J2	*C. freundii*	1	8	1	↗↗↗ Case +TEM-3	1 x 10^2	1 x 10^2
Extended spectrum oxacillinases	2	J3	*K. pneumoniae*	0.5	0.38	0.12	OXA-163	> 1 x 10^4	> 1 x 10^4
	2	J4	*E. cloacae*	0.5	2	0.19	OXA-163	2 x 10^2	> 1 x 10^4
	2	J5	*S. marcescens*	0.5	0.75	0.19	OXA-405	> 1 x 10^4	> 1 x 10^4
CARBAPENEMASE PRODUCERS									
KPC-type	1	F1	*E. coli*	1	>32	3	KPC-2	1 x 10^2	1 x 10^2
	1	F2	*E. coli*	0.5	0.5	0.5	KPC-2	1 x 10^2	1 x 10^2
	1	F3	*E. coli*	2	1.5	1	KPC-2 + TEM-1 + OXA-9	1 x 10^2	1 x 10^2
	1	F4	*E. coli*	4	4	2	KPC-2 + CTX-M-9 + TEM-1	1 x 10^2	4 x 10^2
	1	F5	*K. pneumoniae*	16	24	32	KPC-2 + SHV-11 + TEM-1 + CTX-M-2	1 x 10^2	1 x 10^2
	1	F6	*K. pneumoniae*	>32	>32	>32	KPC-2 + SHV-11 + TEM-1 + CTX-M-2 + OXA-9	1 x 10^2	1 x 10^2
	1	F7	*K. pneumoniae*	16	>32	>32	KPC-2 + SHV-11 + CTX-M-15	1 x 10^2	1 x 10^2
	1	F8	*K. pneumoniae*	4	4	32	KPC-2 + TEM-1 + SHV-1 + CTXM-15	1 x 10^2	1 x 10^2
	1	F9	*K. pneumoniae*	4	24	2	KPC-2 + SHV-11 + TEM-1 + SHV-12 + OXA-9	1 x 10^2	1 x 10^2
	1	F10	*K. pneumoniae*	>32	>32	>32	KPC-2 + SHV-11	1 x 10^2	1 x 10^2
	1	G1	*K. pneumoniae*	4	6	8	KPC-2 + SHV-11 + TEM-1	1 x 10^2	1 x 10^2
	1	G2	*K. pneumoniae*	4	>32	8	KPC-3 + TEM-1 + SHV-1 + CTX-M-15 + OXA-9	1 x 10^2	1 x 10^2
	1	G3	*K. pneumoniae*	8	>32	8	KPC-3 + SHV-11 + OXA-9 + TEM-1	1 x 10^2	1 x 10^2
	1	G4	*K. ozoenae*	>32	>32	2	KPC-3 + OXA-9 + TEM-1	> 1 x 10^4	2 x 10^2

	1	G5	*E. cloacae*	1	1.5	0.75	KPC-2	1×10^2	1×10^2
	1	G6	*E. cloacae*	24	>32	16	KPC-2 + TEM-1	1×10^2	1×10^2
	1	G7	*E. cloacae*	4	6	2	KPC-2 + TEM-1 + OXA-1	1×10^2	1×10^2
	1	G8	*E. cloacae*	2	4	1.5	KPC-2 + TEM-1 + SHV-11	1×10^2	1×10^2
	1	G9	*E. cloacae*	2	2	1	KPC-2 + TEM-3	1×10^2	1×10^2
	1	G10	*C. freundii*	8	1.5	3	KPC-2 + TEM-1	$> 1 \times 10^4$	1×10^2
	1	I1	*S. marcecens*	>32	>32	>32	KPC-2 + TEM-1 + SHV-12	1×10^2	1×10^2
	1	I2	*S. marcecens*	>32	>32	>32	KPC-2 + TEM-1	1×10^2	1×10^2
	1	I3	*E. cloacae*	>32	8	4	IMI-1	$> 1 \times 10^4$	1×10^2
IMI-type	1	I4	*E. asburiae*	>32	>32	>32	IMI-2	$> 1 \times 10^4$	1×10^2
	1	I5	*E. asburiae*	>32	8	2	IMI-2	$> 1 \times 10^4$	3×10^2
NMC-A	1	I6	*E. cloacae*	>32	1,5	0,75	NmcA	$> 1 \times 10^4$	3×10^3
SME-type	1	I7	*S. marcescens*	>32	8	8	Sme-1	$> 1 \times 10^4$	$> 1 \times 10^4$
	1	I8	*S. marcescens*	>32	8	8	Sme-2	$> 1 \times 10^4$	1×10^2
GES-type	1	I9	*E.cloacae*	>32	>32	>32	GES-5	1×10^2	1×10^2
FRI-1	1	I10	*E. cloacae*	>32	>32	16	FRI-1	1×10^2	1×10^2
	1	A1	*E. coli*	1	3	1	NDM-1 + OXA-1 + OXA-10 + CMY-16 + TEM-1	1×10^2	1×10^2
	1	A2	*E. coli*	3	3	2	NDM-1 + OXA-1 + TEM-1	1×10^2	1×10^2
	1	A3	*E. coli*	6	32	16	NDM-1 + CTX-M-15 + TEM-1	1×10^2	1×10^2
	1	A4	*E. coli*	4	>32	8	NDM-1 + OXA-1 + OXA-2 + CTX-M-15 + TEM-1	1×10^2	1×10^2
	1	A5	*E. coli*	16	>32	16	NDM-1 + CTX-M-15 + TEM-1	1×10^2	1×10^2
	1	A6	*E. coli*	>32	>32	>32	NDM-4 + CTX-M-15 + OXA-1	1×10^2	1×10^2
	1	A7	*E. coli*	>32	>32	>32	NDM-4 + CTX-M-15 + CMY-6	1×10^2	1×10^2
	1	A8	*E. coli*	>32	>32	>32	NDM-5 + TEM-1 + CTX-M-15	1×10^2	1×10^2
	1	A9	*E. coli*	6	32	8	NDM-6 + CTX-M-15 + OXA-1	1×10^2	1×10^2
	1	A10	*E. coli*	4	16	3	NDM-7	1×10^2	1×10^2
NDM-type	1	B1	*K. pneumoniae*	2	8	3	NDM-1 + CTX-M-15 + SHV-11 + OXA-1	1×10^2	1×10^2
	1	B2	*K. pneumoniae*	>32	>32	>32	NDM-1 + CTX-M-15 + CMY-4 + OXA-1	1×10^2	1×10^2
	1	B3	*K. pneumoniae*	>32	>32	>32	NDM-1 + CTX-M-15 + OXA-1 + OXA-9 + TEM-1 + SHV-28 + SHV-11	1×10^2	1×10^2
	1	B4	*K. pneumoniae*	1.5	6	2	NDM-1 + OXA-1 + SHV-11	1×10^2	1×10^2
	1	B5	*K. pneumoniae*	1	8	4	NDM-1 + OXA-1 + CTX-M-15 + TEM-1 + SHV-28 + OXA-9 + CMY-6	1×10^2	1×10^2
	1	B6	*K. pneumoniae*	1.5	8	1.5	NDM-1 + TEM-1 + CTX-M-15 + SHV-12 + OXA-9	1×10^2	1×10^2
	1	B7	*K. pneumoniae*	4	8	16	NDM-1 + TEM-1 + CTX-M-15 + SHV-12 + OXA-9	1×10^2	1×10^2
	1	B8	*K. pneumoniae*	2	>32	4	NDM-1 + TEM-1 + CTX-M-15 + SHV-11 + OXA-1	1×10^2	1×10^2
	1	B9	*P. stuartii*	12	0.38	1.5	NDM-1 + OXA-1 + CMY-6 + TEM-1	1×10^2	$> 1 \times 10^4$
	1	B10	*P. rettgeri*	3	0.5	1.5	NDM-1 + CTX-M-15	1×10^2	1×10^2
	1	C1	*Salmonella enterica*	4	6	3	NDM-1 + CTX-M-15 + TEM-1 + OXA-1 + OXA-9 + OXA-10	5×10^2	2×10^2
	1	C2	*E. coli*	1.5	0.38	0.5	VIM-1 + CTX-M-3	1×10^2	$> 1 \times 10^4$
VIM-type	1	C3	*E. coli*	3	1.5	1	VIM-1 + CMY-13	2×10^3	6×10^2
	1	C4	*E. coli*	8	4	3	VIM-4	1×10^2	1×10^2
	1	C5	*K. pneumoniae*	>32	>32	>32	VIM-1 + SHV-5	1×10^2	1×10^2

	1	C6	*K. pneumoniae*	>32	>32	>32	VIM-1	1×10^2	1×10^2
	1	C7	*K. pneumoniae*	>32	>32	>32	VIM-1 + SHV-12	1×10^2	1×10^2
	1	C8	*K. pneumoniae*	>32	>32	>32	VIM-1	1×10^2	1×10^2
	1	C9	*K. pneumoniae*	4	2	2	VIM-1 + SHV-5	1×10^2	1×10^2
	1	C10	*K. pneumoniae*	>32	>32	>32	VIM-1 + TEM-1 + SHV-5	1×10^2	1×10^2
	1	D1	*K. pneumoniae*	>32	>32	>32	VIM-1 + SHV-5	1×10^2	1×10^2
	1	D2	*K. pneumoniae*	1	0.5	1	VIM-1 + CTX-M-3	1×10^2	1×10^2
	1	D3	*K. pneumoniae*	0.5	4	0.38	VIM-1 + SHV-5	1×10^2	1×10^2
	1	D4	*K. pneumoniae*	8	16	4	VIM-19 + CTX-M-3 + TEM-1 + SHV-1	1×10^2	1×10^2
	1	D5	*E.cloacae*	1	0.38	0.5	VIM-1 + SHV-70	1×10^2	3×10^2
	1	D6	*E. cloacae*	3	2	1	VIM-4 + CTX-M-15 + TEM-1 + SHV-31	1×10^2	1×10^2
	1	D7	*C. freundii*	2	2	0.75	VIM-2 + TEM-1 +	1×10^2	1×10^2
	1	D8	*C. freundii*	1.5	4	0.5	VIM-2 + TEM-1 + OXA-9 + OXA-10	1×10^2	1×10^2
	1	D9	*E. coli*	0.5	3	0.5	IMP-1	1×10^2	1×10^2
	1	D10	*E. coli*	6	8	3	IMP-8 + SHV -12	1×10^2	1×10^2
	1	E1	*K. pneumoniae*	1.5	3	1	IMP-1	1×10^2	1×10^2
	1	E2	*K. pneumoniae*	8	3	2	IMP-1 + TEM-15	1×10^2	1×10^2
	1	E3	*K. pneumoniae*	1.5	4	2	IMP-1 + TEM-15 + CTX-M-15	1×10^2	1×10^2
IMP-type	1	E4	*K. pneumoniae*	1	2	8	IMP-1 + SHV-5	1×10^2	1×10^2
	1	E5	*K. pneumoniae*	1	1	0.5	IMP-8	1×10^2	1×10^2
	1	E6	*K. pneumoniae*	0.5	0.5	0.5	IMP-8 + SHV -12	1×10^2	1×10^2
	1	E7	*E. cloacae*	1.5	1	1	IMP-8	1×10^2	1×10^2
	1	E8	*E. cloacae*	0.75	0.5	0.5	IMP-8 + SHV-12	1×10^2	1×10^2
	1	E9	*S. marscecens*	8	>32	2	IMP-11	1×10^2	1×10^2
GIM-type	1	E10	*E. cloacae*	2	>32	6	GIM-1	1×10^2	1×10^2
	2	A1	*E. coli*	3	16	1	OXA-48 + CTX-M-15	1×10^2	1×10^2
	2	A2	*E. coli*	0.5	0.75	0.12	OXA-48 + CTX-M-15	1×10^2	1×10^2
	2	A3	*E. coli*	0.38	1.5	0.19	OXA-48 + CTX-M-15	1×10^2	1×10^2
	2	A4	*E. coli*	0.25	0.5	0.19	OXA-48 + CTX-M-24 + TEM-1	1×10^2	1×10^2
	2	A5	*E. coli*	0.75	1	0.19	OXA-48 + CTX-M-24 + TEM-1	1×10^2	1×10^2
	2	A6	*E. coli*	0,5	1	0.25	OXA-48 + CTX-M-15	1×10^2	2×10^2
	2	A7	*K. pneumoniae*	0.5	2	0.5	OXA-48	2×10^3	1×10^2
OXA-48	2	A8	*K. pneumoniae*	0.38	1	0.5	OXA-48 + TEM-1	$\underline{> 1 \times 10^4}$	1×10^2
	2	A9	*K. pneumoniae*	2	3	2	OXA-48 + CTX-M-15	1×10^2	1×10^2
	2	A10	*K. pneumoniae*	1	4	1	OXA-48	$\underline{> 1 \times 10^4}$	1×10^2
	2	B1	*K. pneumoniae*	1	4	1	OXA-48	$\underline{> 1 \times 10^4}$	1×10^2
	2	B2	*K. pneumoniae*	>32	>32	>32	OXA-48	6×10^3	1×10^2
	2	B3	*K. pneumoniae*	0.5	0.75	0.25	OXA-48 + SHV-11	$\underline{> 1 \times 10^4}$	1×10^2
	2	B4	*K. pneumoniae*	0,5	>32	1,5	OXA-48 + CTX-M-15 + TEM -1	1×10^2	1×10^2
	2	B5	*K. pneumoniae*	0.75	16	1	OXA-48 + CTX-M-15 + TEM-1	1×10^2	1×10^2
	2	B6	*E. cloacae*	0.5	2	0.5	OXA-48 + TEM-1 + CTX-M-15 + OXA-1	1×10^2	1×10^2

	2	B7	*E. cloacae*	1	16	1.5	OXA-48 + TEM-1 + CTX-M-15 + OXA-1	1×10^2	1×10^2
	2	B8	*E. cloacae*	2	8	1	OXA-48 + SHV-5	1×10^2	1×10^2
	2	B9	*C. koseri*	0.38	2	0.38	OXA-48	1×10^3	1×10^2
	2	B10	*C. koseri*	0.75	2	0.38	OXA-48 + TEM-1	1×10^2	1×10^2
	2	C1	*C. freundii*	0.75	1,5	0.38	OXA-48 + SHV-12 + TEM-1	1×10^2	1×10^2
OXA-162	2	C2	*K. pneumoniae*	4	8	1	OXA-162 + TEM-1 + SHV-11	1×10^2	1×10^2
	CNR 67 F9		*K. pneumoniae*	0.38	8	0.5	OXA-162	$> 1 \times 10^4$	1×10^2
	2	C3	*E. coli*	0.38	1.5	0.19	OXA-181	1×10^3	1×10^2
	2	C4	*E. coli*	0.5	1.5	0.25	OXA-181	$> 1 \times 10^4$	1×10^4
	CNR 51 E10		*E. coli*	0.38	0.38	0.12	OXA-181	1×10^2	1×10^4
	CNR 59 F5		*E. coli*	0.38	1.5	0.12	OXA-181	1×10^2	1×10^2
OXA-181	CNR 61 C6		*E. coli*	0.25	1	0.12	OXA-181	1×10^2	1×10^2
	CNR 61 D1		*E. coli*	0.25	1.5	0.12	OXA-181	1×10^2	1×10^2
	CNR 64 C4		*E. coli*	>32	>32	12	OXA-181	1×10^2	1×10^2
	2	C9	*K. pneumoniae*	0.5	2	0.5	OXA-181 + SHV-11 + CTXM-15 + OXA-1	1×10^2	1×10^2
	CNR 58 J8		*K. pneumoniae*	0.38	1.5	0.38	OXA-181	1×10^2	1×10^2
	2	D2	*K. pneumoniae*	0.5	2	0.5	OXA-204 + CMY-4	1×10^2	1×10^2
	2	D3	*E. coli*	0.38	0.19	0,094	OXA-204 + CMY-2 + CTX-M-15 + OXA-1	1×10^2	1×10^2
OXA-204	2	D4	*E. coli*	0,5	2	0.25	OXA-204 + CMY-4+ CTX-M-15 + OXA-1	1×10^2	1×10^4
	2	D5	*E. coli*	0,5	2	0.38	OXA-204 + CMY-4 + CTX-M-15	1×10^2	1×10^3
	2	D6	*K. pneumoniae*	0,5	16	0.75	OXA-204 + SHV-28 + TEM-1 + CTX-M-15	1×10^2	1×10^2
	2	D7	*E. coli*	>32	>32	>32	OXA-232 + CTX-M-15 + OXA-1	1×10^2	1×10^2
OXA-232	2	D8	*K. pneumoniae*	3	>32	12	OXA-232 +SHV-1 + TEM-1 + CTX-M-15 + OXA-1	1×10^2	1×10^2
	CNR 68 B2		*E. coli*				OXA-232	$> 1 \times 10^4$	1×10^2
OXA-244	2	D9	*E. coli*	0.5	2	0.5	OXA-244 + TEM-1 + CMY-2	$> 1 \times 10^4$	1×10^2
	2	D10	*E. coli*	0.5	1.5	0.5	OXA-244 + TEM-1 + CMY-2	1×10^2	1×10^2
OXA-372	2	J6	*C. freundii*	3	2	0.5	OXA-372 + CMY-135 + OXA-10 + MOX-9	1×10^2	1×10^2
	2	C5	*K. pneumoniae*	3	>32	4	OXA-181 + SHV-11 + TEM-1 + CTX-M-15 + NDM-1 + OXA-1	1×10^2	1×10^2
	2	C6	*K. pneumoniae*	>32	>32	>32	OXA-181 + SHV-27 + CTX-M-15 + TEM-1 + NDM-1 + OXA-1	1×10^2	1×10^2
	2	C7	*K. pneumoniae*	>32	>32	>32	OXA-181 + SHV-11 + CTX-M-15 + NDM-1 + OXA-1	1×10^2	1×10^2
	2	C8	*K. pneumoniae*	16	>32	>32	OXA-181 + SHV-11 + TEM-1 + CTX-M-15 + NDM-1 + OXA-9	1×10^2	1×10^2
	2	C10	*K.pneumoniae*	0.5	2	0.5	OXA-181 + NDM-1 + SHV-2 + CTX-M-15 + OXA-1	1×10^2	1×10^2
	2	D1	*C.freundii*	>32	>32	16	OXA-181 + NDM-1 + OXA-1 + OXA-9 + OXA-10 + CTX-M-15 + TEM-1	1×10^2	1×10^2
Multiple	CNR 60 A6		*E. coli*	16	>32	16	NDM-1 + OXA-48	1×10^2	1×10^2
carbapenemases	CNR 63 C5		*E. coli*	2	>32	3	NDM-1 + OXA-48	1×10^2	1×10^2
	CNR 67 D2		*E. coli*	1.5	>32	3	NDM-1 + OXA-48	1×10^2	1×10^2
	CNR 22 F9		*K. pneumoniae*	4	>32	8	NDM-1 + OXA-232	1×10^2	1×10^2
	CNR 46 A8		*E. coli*	2	>32	6	NDM-1 + OXA-232	1×10^2	1×10^2
	CNR 28 10		*K. pneumoniae*	>32	>32	>32	NDM-5 + OXA-232	1×10^2	1×10^2
	CNR 51 A9		*E. coli*	0.75	1	0.38	NDM-1 + VIM-2	1×10^2	1×10^2
	CNR 45 J4		*E. cloacae*	1	3	0.75	VIM-4 + OXA-48	1×10^2	1×10^2

[a] Abbreviations : IPM, imipenem; ETP, ertapenem, MEM, meropenem, ↗↗↗ Case, overexpressed cephalosporinase
[b] One ml of stools contains 100 mg of stool.
[c] Underlined CFU counts are considered as negative results (cut-off values set at $\geq 1 \times 10^4$ CFU/ ml).